Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Cp (NQ: TECH )

80.73 -1.22 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 581,119
Open 81.27
Bid (Size) 70.06 (2)
Ask (Size) 82.56 (1)
Prev. Close 81.95
Today's Range 79.69 - 82.31
52wk Range 79.44 - 522.96
Shares Outstanding 39,242,384
Dividend Yield 1.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Bio-Techne: Q1 Earnings Insights
Bio-Techne (NASDAQ:TECH) reported its Q1 earnings results on Tuesday, November 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-83.45%
-83.45%
1 Month
-74.21%
-74.21%
3 Month
-76.72%
-76.72%
6 Month
-75.87%
-75.87%
1 Year
-82.83%
-82.83%

More News

Read More
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Recap: Bio-Techne Q4 Earnings
Via Benzinga
Earnings Scheduled For November 1, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Recap: Bio-Techne Q3 Earnings
Via Benzinga
Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback
Via Benzinga
Earnings Scheduled For November 2, 2021
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Tackling Recurring Health Conditions Offers Hope to Patients
Via FinancialNewsMedia
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
7 Defensive Growth Stocks to Buy for a Shaky Market
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Superior Stocks That Smart Investors Will Buy on the Dip
Via InvestorPlace
10 Biggest Price Target Changes For Wednesday
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Via Benzinga
Here's How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years
Via Benzinga
Bio-Techne Corporation (TECH) Q1 2022 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Via Benzinga
Exposures COVID-19
Bio-Techne's Earnings: A Preview
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.